US53635D2027 - Common Stock
LIQUIDIA CORP
NASDAQ:LQDA (11/14/2024, 8:00:00 PM)
After market: 10.34 +0.31 (+3.14%)10.025
-0.24 (-2.39%)
Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. The company is headquartered in Morrisville, North Carolina and currently employs 136 full-time employees. The company went IPO on 2018-07-26. The firm is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The firm operates through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
LIQUIDIA CORP
419 Davis Drive, Suite 100
Morrisville NORTH CAROLINA 27560
P: 19193284400
CEO: Neal Fowler
Employees: 136
Website: https://www.liquidia.com/
Liquidia Corporation (LQDA) today reported financial results for the third quarter ended September 30, 2024....
Liquidia Corporation (LQDA) to present at the Stifel 2024 Healthcare Conference in New York City on Tuesday, November 19, 2024, from 3:00 – 3:30 p.m. ET. ...
Here you can normally see the latest stock twits on LQDA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: